Foundation Medicine Launches FoundationOne™ Heme, Developed in Collaboration with Memorial Sloan-Kettering Cancer Center
FoundationOne Heme, Foundation Medicine's Second Clinical Product, is a Fully Informative Genomic Profile for Hematologic Malignancies, Sarcomas and Pediatric Cancers
"By introducing our second clinical product, FoundationOne Heme, in only our second year of commercialization, we are demonstrating our commitment to ongoing product innovation to make molecular information broadly available to the hematology and oncology communities at academic medical centers and community hospitals worldwide," said Michael J. Pellini, M.D., president and chief executive officer of
FoundationOne Heme uses comprehensive, clinical next-generation sequencing (NGS) to assess routine cancer specimens for all genes that are currently known to be somatically altered and unambiguous drivers of oncogenesis in hematologic malignancies, as well as many sarcomas and pediatric cancers. Utilizing NGS, FoundationOne Heme simultaneously detects all classes of genomic alterations, including base pair substitutions, insertions and deletions, copy number alterations and select gene rearrangements in 405 cancer-related genes. In addition to DNA sequencing, FoundationOne Heme employs RNA sequencing across 265 genes to capture a broad range of gene fusions, a type of alteration that is a common driver of hematologic cancers, sarcomas and pediatric cancers. FoundationOne Heme fits easily into the clinical workflow of the ordering physician, and test results are provided in an easy-to-interpret report supported by a comprehensive review of published literature.
"Our vision is to make cancer genomic testing available in routine care to enable more precise and informed treatment decisions for patients with a broad range of cancers," added
New data from ten studies demonstrating the utility of FoundationOne Heme in hematologic malignancies will be presented during the 2013
About FoundationOne™ Heme
FoundationOne Heme is a fully informative genomic profile for hematologic cancers (leukemia, lymphoma and myeloma), as well as many sarcomas and pediatric cancers, designed to provide physicians with clinically actionable information to guide treatment options for patients based on the genomic profile of their cancer. It is Foundation Medicine's second commercially available targeted sequencing assay and was developed in collaboration with
About
The close collaboration between physicians and scientists enables Memorial Sloan-Kettering to provide patients with the best care available as they work to discover more-effective strategies to prevent, control, and ultimately cure cancer in the future. Memorial
About
Foundation Medicine® is a registered trademark, and FoundationOneTM is a trademark, of
Cautionary Notes Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the commercial launch of FoundationOneTM Heme, the design, development and commercialization of FoundationOne Heme, the ease of use of FoundationOne Heme in routine clinical practice, the delivery of relevant genomic information in the FoundationOne Heme report, the benefits to patients with hematologic cancers of next-generation sequencing , and the release of data and studies related to the utility of FoundationOne Heme. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risks that FoundationOne Heme may not meet the clinical standards expected for the test, or may not achieve significant commercial adoption or reimbursement support; that
1. Alterations are defined as clinically actionable if linked to an
Media Contact:
dan@purecommunicationsinc.com
or
hoolc@mskcc.org
or
Investor Contact:
ir@foundationmedicine.com
Source:
News Provided by Acquire Media